Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Phase 2a heart failure trial begins
August 2014
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SAN DIEGO—CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary, has begun a Phase 2a clinical trial for chronic heart failure, the first launch in the company’s heart failure (HF) program. The study will seek to evaluate the safety, tolerability and preliminary efficacy of an intravenous dose of ischemia-tolerant allogeneic mesenchymal bone marrow cells in patients with non-ischemic cardiomyopathy.
 
“CardioCell consulted the world’s leading cardiologists to accelerate our vision for creating breakthrough, allogeneic stem-cell therapies to help patients suffering from chronic HF,” said CardioCell President and CEO Dr. Sergey Sikora. “CardioCell’s Phase 2a clinical trial uses our unique, hypoxically grown stem cells to address non-ischemic cardiomyopathy, a complex condition in which patients have living cardiomyocytes that are not contracting as they should. We hope our itMSCs will assist in reactivating these cardiomyocytes that could, eventually, restore heart function.”
 
Code:

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.